Combination Therapy with a Bispecific Antibody Targeting the hERG1/β1 Integrin Complex and Gemcitabine in Pancreatic Ductal Adenocarcinoma

SIMPLE SUMMARY: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers and is forecasted to become the second most common cause of cancer-related deaths by 2030. Its therapy has proven extremely difficult and, consequently, there is an urgent need for novel therapeutic strategies fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Lottini, Tiziano, Duranti, Claudia, Iorio, Jessica, Martinelli, Michele, Colasurdo, Rossella, D’Alessandro, Franco Nicolás, Buonamici, Matteo, Coppola, Stefano, Devescovi, Valentina, La Vaccara, Vincenzo, Coppola, Alessandro, Coppola, Roberto, Lastraioli, Elena, Arcangeli, Annarosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093586/
https://www.ncbi.nlm.nih.gov/pubmed/37046674
http://dx.doi.org/10.3390/cancers15072013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093586/
https://www.ncbi.nlm.nih.gov/pubmed/37046674
http://dx.doi.org/10.3390/cancers15072013

Ejemplares similares